Key points
- Discovery of (E,E)-bisantrene as a potent MYC gene silencer
- Expansion of clinical programs to include AML and NSCLC
- Successful capital raising of $34.3 million
- Development of a novel blood-based molecular test for cardioprotection
- Change of company name from Race Oncology to Racura Oncology
Full summary
Racura Oncology Ltd's Annual Report for FY2026 highlights transformative discoveries in the mechanism of action of (E,E)-bisantrene, identifying it as a potent silencer of the MYC gene. This breakthrough has opened new clinical opportunities across acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). The company expanded its clinical programs, including the HARNESS-1 trial for NSCLC and a Phase 3 program for AML. Additionally, Racura successfully raised $34.3 million to fund these initiatives, developed a novel blood-based molecular test for cardioprotection, and rebranded from Race Oncology to Racura Oncology, symbolizing a new chapter in its journey.
Guidance
Racura Oncology Ltd is funded to support activities into CY2028.
Outlook
Racura Oncology Ltd aims to initiate its pivotal AML program, continue advancement of HARNESS-1 and CPACS trials, and pursue strategic partnerships and licensing opportunities.